Young J A, Westlake D, Schnetzer G W, Keller A M, Sexauer J M, Newcomer L N
Cancer Treat Rep. 1985 Jun;69(6):607-10.
Thirty-one patients with advanced malignancy received vinblastine as an iv bolus at 0 and 48 hours of a 21-day cycle. Divided-dose vinblastine may be given with acceptable toxicity in heavily pretreated patients; leukopenia and neuropathy were the dose-limiting toxic effects. One patient with breast cancer and one with ovarian cancer responded. Serum vinblastine levels with this program approximate those achieved by a 5-day continuous infusion of vinblastine in standard dose.
31例晚期恶性肿瘤患者在21天周期的第0天和第48小时接受长春花碱静脉推注。对于预处理程度较高的患者，分次给药的长春花碱可能具有可接受的毒性；白细胞减少和神经病变是剂量限制性毒性反应。1例乳腺癌患者和1例卵巢癌患者有反应。采用该方案时血清长春花碱水平接近标准剂量长春花碱5天持续输注所达到的水平。
